Lung malignancy Flashcards

1
Q

Most common cancer and cancer death in both males and female

A

LUNG cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Risk Factors of Lung cancer

A

SMOKING

one gentic mutation is induced for every 15 cigarettes smoked

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The best known risk factor in developing ANY cancer

A

AGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

High associated with lung cancer and mesothelioma

A

Asbestos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cancer development

A

Genetic and Environmental factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Polymorphic variations in the genes…

A

p53 and retinoblastoma suppressor gene expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The process when carcinogen confers a genetic change on the normal cell

A

Initiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Happens when those genetic changes confers a growth advantage on the cell over its neighboriing cells

A

Promotion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lung cancer gene mutations

A

EGFR - cancer susceptibility to never smokers

P450 enzyme system specifically CYP1A1

RB

p53 *Li-Fraumeni syndrome) - 1st degree relatives of lung CA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hallmarks of Cancer

A

Self sufficiency in growth signals

Insensitivity to antigrowth signals

Tissue invasion and metastasis

Limitless replicative potential

Sustained angiogenesis

Evading apoptosis

Avoidance of host immune system

Tumor promoting inflammation involved

Develop ability to deregulate cellular energetics

Develop genomic instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Epithelial tumors of the lung counts for 90% of epithelial tumors of the lung counts for 90% of epithelial tumors

A

Bronchogenic carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

NSCLC type

A

Adenocarcinoma
SQCCA
Large cell CA

Account for 90% of all epithelial cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Squamous cell lung CA

A

Typically central and close to carina
Frequently presenting with bronchial obstruction and hemoptysis

Highly associated with cigarette smoking

More common in men than in women

areas of squamous metaplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOST frequent histologic subtype of NSCLC

A

Adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Contains sheet of cells rather than 3D group of cells as with the case of adenocarcinoma

A

Squamous cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Possess a glandular differentiation or mucin production

Typically peripheral, sometimes originating in areas of pre-existing lung scarring

A

Adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Most common histology found in never smokers, and also in women

A

Adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Adenocarcinoma may manifest as:

A

Adenocarcinoma in situ

Minimally invasive

Invasive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Main histological patterns of adenocarcinoma

A

Acinar - gland like spaces

Papillary - leaf like thin septa

Solid carcinoma with mucin production - Poorly differentiated

Lepidic mixed subtype tumors with non-mucinous bronchioalveolar CA

Micropapillary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Marker for adenocarcinoma

A

TTF 1 or napsin A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

marker for squamous CA

A

p40 or p63 and/or mucin stains

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Lung adenocarcinomas can arise when tumorrs express this mutant gene

A

EGFR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What type of cells have the capacity to give rise to adenocarcinoma

A

Type II epithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

LArge malignant cells without evidence of squamous of glandular differentiation

A

Large cell CA

25
Macroscopic features of large ccell CA
Peripheral | maybe central
26
Histological features of large CA
Large malignant cells that lack the cytologic and architectural features of small cell CA and glandular or squamous differentiation
27
Undifferentiated/oat cell Carcinoma
Squamous cell CA
28
Histological characteristic of small cell CA
salt and pepper pattern (Very scant cytoplasm, small, hyperchromatic nuclei with a fine chromatin pattern and absent/inconspicuous nucleoli
29
Cell of origin for small cell carcinoma
Kulchitsky cells
30
Type of cancer that secrets a lot of polypeptide hormones such as ACTH, AVP, ANF, and GRP
Small cell Carcinoma
31
Lung cancer associated with a lot of paraneoplastic syndromes
small cell CA
32
Clinical signs of lung malignancy
``` Cough (80%) Hemoptysis (70%) Dyspnea (60%) Chest pain (40%) Recurrent or slowly resolving pneumonia Constitutional signs Cachexia Supraclavicular or axillary LAD Tender ribs ```
33
Signs of Mediastinal compression
SVC syndrome - facial edema, NVE, plethora, dysphagia, dyspnea ``` Facial edema Telagiectasia Hypotension latter part Flushing Neck vein engorgement ```
34
A tumor that occupies the apex of the lung might affect the nerve specifically ulnar nerve which can result to arm pain
Pancoast Tumor C8, T1 and T2
35
Metastatic signs and symptoms
Bone Pain and tenderness hepatomegaly and jaundice Confsuion and neurologic signs Nausea, vomiting, headache
36
Hypertrophic Pulmonary Osteoarthropathy
Clubbing Periostitis commonly found in small cell lung CA swelling pain
37
Hypercalcemia (PNPS)
most common oncologic emergency Increase PTH
38
Paraneoplastic syndrome
``` hypercalcemia Cushing's syndrome Carcinoid syndrome Gynecomastia Hypoglycemia ```
39
Carcinoid syndrome (serotonin)
``` Irregular mottled blushing Flat angiomas of the skin Acquired tricuspid and pulmonary stenosis Diarrhea Bronchial Spasm Mental aberratiion Excretion of large quantities of 5-HIAA ```
40
Neurological syndrome found in small lung CA
Eaton-lambert syndrome
41
Progressive proximal muscle weakness in the absence of dermatomyositis
Eaton-Lambert Syndrome
42
Migrating venous thrombophlebitis
Trousseau syndrome
43
Establishes a cytologic and/or histologic diagnosis in 80-85% of centrally located lesions
Bronchoscopy
44
Four types of specimens
Bronchial brush Bronchial washing Bronchoalveolar lavage transbronchial FNAB - most sensitive
45
May diagnose up to 90% of peripheral lung cancers
CT guided transthoracic needle biopsy
46
Provides not only histologic dx but also important staging information
Mediastinoscopy
47
Scan good for staging
PET Scan
48
Checks for the level of glucose metabolism by cells
PET - uses FDG 18 - uses scorring called standardized Uptake Values
49
Tumor component (2018)
``` < = 1 cm =T1a >1-2 cm = T1b >2-3cm = T1c >3-4 cm = T2a >4-5cm = T2b >5-7 cm = T3 >7 cm = T4 ```
50
M component (2018)
Within the thoracic = M1a Single extrathoracic = M1b Multiple extrathoracic = M1c
51
Node invovlement
``` N0 = no nodes N1 = ipisilateral bronchopulmonary N2 = Ipsilateral or subcarinal N3 = contralateral hilar/mediatinal and ipsilateral ```
52
Treatment for Lung CA
I - Cure II - Cure III and IV - Control of local disease and increase length of survival
53
Surgical treatment
Wedge resection - not form small cell CA Lobectomy - small tumors Pneumonectomy - large tumors
54
Backbone of CRx treatment
Cisplatin/Carboplatin
55
Anti EGFR
Gefitiib - forst approved tyrosine kinase inhibitor Erlotinib - 1st-3rd line tx of metastatic NSCLC Afatinib - 2nd generation tyrosine kinase inhibitor Ceftuximab
56
ALK inhibitors
Crizotinib - targets EML4/ALK fusion protein Ceritinib Alectinib
57
Bevacizumab
VEGF inhibitor
58
Immunotherapy
PD-1/PD-L1 interaction -mediates inhibition of T cell mediated tumor cell killing and inhibition of T cell activation nivolumab, pembrolizumab